证券代码：688317 证券简称：之江生物 公告编号：2025-062 上海之江生物科技股份有限公司 关于自愿披露公司产品获得相关认证的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）1 项产品于近期获得 国家三类医疗器械注册证，现将具体情况公告如下： 一、医疗器械注册证具体情况 | 注 | 册 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 产品名称 | 证书编号 | 注册证有效期 | 适用范围 | 分 | | | | | | | | | | | 类 | 新型冠状病毒 | 2019-nCoV | 2025 | 年 | 10 | 月 | 27 | 新 | 型 | 冠 | 状 | 病 | 毒 | | 国 | 械 | 注 | 准 | 核酸检测试剂盒（荧光 | PCR | 日至 | 2030 | 年 ...

Core Viewpoint - The company has recently obtained a Class III medical device registration certificate for a new product, which is a nucleic acid detection kit for the novel coronavirus 2019-nCoV, indicating a significant advancement in its product offerings and potential market impact [1] Group 1: Product Details - The product is named "Nucleic Acid Detection Kit for Novel Coronavirus 2019-nCoV (Fluorescent PCR Method)" [1] - The registration certificate number is 20253402166, with a validity period from October 27, 2025, to October 26, 2030 [1] - The product utilizes mature fluorescent PCR technology and lyophilization processes, aimed at providing a precise and convenient detection tool for clinical use [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-060 上海之江生物科技股份有限公司 关于 2025 年前三季度转回资产减值准备的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 28 日，上海之江生物科技股份有限公司（以下简称"公司"） 召开第五届董事会第十七次会议，审议通过了《关于 2025 年前三季度转回资产 减值准备的议案》，该议案无需提交公司股东会审议，现将具体事宜公告如下： 一、转回资产减值准备情况概述 根据《企业会计准则》和公司会计政策、会计估计的相关规定，为客观、公 允地反映公司 2025 年 9 月 30 日的财务状况和 2025 年前三季度的经营成果，公 司及下属子公司对截至 2025 年 9 月 30 日的公司资产进行了充分的评估和分析， 本着谨慎性原则，公司对相关资产进行了全面清查和减值测试。经测算，2025 年前三季度公司转回减值损失共计 16,497,013.80 元，具体情况如下： 单位：人民币元 | | | | 项目 | 前三季度转回金额 | | - ...

上海之江生物科技股份有限公司 关于开展外汇衍生品交易业务的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海之江生物科技股份有限公司（以下简称"公司"）为有效防范并降 低外汇市场波动风险，以降低汇率大幅波动可能对公司经营业绩带来的影响，公 司及合并范围内的子公司拟开展外汇衍生品交易业务,预计交易额度不超过 2,000 万美元（或等值其他货币）。交易业务主要包括但不限于：外汇远期、外 汇掉期、外汇期权、结构性远期及其他外汇衍生品产品业务。公司及合并范围内 的子公司拟开展外汇衍生品交易业务的交易对手为经监管机构批准、具有外汇衍 生品业务经营资质且经营稳健、资信良好的境内大型银行等金融机构。上述交易 额度自 2025 年第二次临时股东会通过之日起 12 个月内有效，有效期内可以滚动 使用。 已履行的审议程序：公司于 2025 年 10 月 28 日召开第五届董事会第十七 次会议，审议通过了《关于开展外汇衍生品交易业务的议案》，该议案尚需提交 公司 2025 年第二次临时股东会审议。 特别风险提示：公司拟开展 ...

证券代码：688317 证券简称：之江生物 公告编号：2025-061 上海之江生物科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 14 日 14 点 00 分 召开地点：上海市闵行区陈行路 2388 号 8 幢 102 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 不涉及 二、 会议审议事项 本次股东会审议议案及投票股东类型 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30 ...

Core Viewpoint - Zhijiang Biology (688317.SH) reported a significant decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 30.75 million yuan, representing a year-on-year decrease of 28.46% [1] - The net profit attributable to shareholders of the listed company was -19.53 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -24.00 million yuan [1]

Financial Performance - The company's operating revenue for the third quarter was ¥30,749,789.88, a decrease of 28.46% compared to the same period last year[3]. - The total profit for the third quarter was a loss of ¥18,338,008.92, with a year-to-date loss of ¥25,938,257.20[3]. - The net profit attributable to shareholders for the third quarter was a loss of ¥19,526,883.18, and the year-to-date loss was ¥29,377,855.95[3]. - The company experienced a 34.27% decline in operating revenue year-to-date, primarily due to decreased product sales and price reductions from centralized procurement policies[8]. - Total operating revenue for the first three quarters of 2025 was ¥90,432,870.13, a decrease of 34.2% compared to ¥137,579,847.20 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was a loss of ¥29,377,855.95, compared to a loss of ¥13,009,588.94 in 2024, representing a deterioration of 126.5%[19]. Research and Development - Research and development expenses totaled ¥12,727,608.42 for the quarter, accounting for 41.39% of operating revenue, an increase of 7.25 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were ¥42,058,199.29, an increase of 7.6% from ¥39,074,589.30 in 2024[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,721,101,815.28, a decrease of 1.82% from the end of the previous year[4]. - The total amount of current assets as of September 30, 2025, is approximately ¥2.94 billion, slightly increased from ¥2.93 billion in the previous year[14]. - Total assets amount to ¥3.72 billion, down from ¥3.79 billion in the previous year[14]. - Non-current assets total ¥783.24 million, a decrease from ¥854.34 million year-over-year[14]. - The total liabilities increased to ¥327,172,042.30 in 2025, compared to ¥153,063,328.61 in 2024, indicating a significant rise[16]. - The total equity attributable to shareholders decreased to ¥3,393,929,772.98 in 2025 from ¥3,636,886,762.51 in 2024, a decline of 6.7%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥32,672,416.67, a decrease of 23.89% compared to the previous year[3]. - Cash inflow from operating activities totaled ¥172,091,272.35 in 2025, down 29.3% from ¥243,668,973.36 in 2024[22]. - The cash flow from sales of goods and services was ¥120,213,144.22 in 2025, down 24% from ¥158,023,714.74 in 2024[22]. - The net cash flow from operating activities was $32,672,416.67, a decrease of 24% compared to $42,926,358.23 in the previous period[23]. - The total cash outflow from operating activities was $139,418,855.68, compared to $200,742,615.13 previously, showing a reduction in operational cash outflows[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,435[11]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, representing 33.81% of total shares[11]. - The company has a total of 14,638,308 shares in its repurchase account, accounting for 7.62% of total shares[13]. - The company has no significant changes in the participation of major shareholders in margin trading or securities lending[13]. Other Financial Metrics - The weighted average return on net assets was -0.56%, an increase of 0.47 percentage points compared to the previous year[4]. - The basic earnings per share for the third quarter was -¥0.10, with a year-to-date figure of -¥0.16[4]. - The company reported non-recurring gains and losses totaling ¥4,477,565.75 for the quarter[7]. - The company reported a financial expense of -¥31,340,122.83 in 2025, a significant improvement from -¥67,266,345.27 in 2024[18]. - The company recorded a credit impairment loss of ¥1,168,467.86 in 2025, compared to a recovery of -¥215,377.15 in 2024[19]. - The company paid $57,114,359.51 in employee compensation, which is lower than $78,188,799.34 in the previous period[23]. - The company experienced a foreign exchange loss of -$9,676,055.88, compared to -$10,932,424.75 in the prior period[23]. - The company has not disclosed any new strategies or future outlook in the provided documents[12].

Core Insights - The company reported a third-quarter revenue of 30.75 million yuan, representing a year-on-year decline of 28.46% [1] - The net profit for the third quarter was a loss of 19.53 million yuan [1] - For the first three quarters, the total revenue was 90.43 million yuan, down 34.27% year-on-year [1] - The net profit for the first three quarters was a loss of 29.38 million yuan [1]

关于 2025 年第三次以集中竞价交易方式回购股份的回 购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2025-058 重要内容提示： 上海之江生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易方 式回购部分公司已发行的普通股（A 股）股份，主要内容如下： ● 回购股份金额：不低于人民币 6,000 万元（含），不超过人民币 12,000 万 元（含）。 上海之江生物科技股份有限公司 ● 回购股份资金来源：公司自有资金和股票回购专项贷款资金。公司已取得 北京银行股份有限公司上海分行出具的《贷款承诺函》，具体贷款事宜将以双方签 订的贷款合同为准。 ● 回购股份用途：回购的股份拟用于员工持股计划或股权激励。 ● 回购股份价格：不超过人民币 37.99 元/股（含），该价格不高于公司董事 会通过回购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自公司董事会审议通过本次回购方案之日起 12 个月 ...

上海之江生物科技股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2025-057 二、前十名无限售条件股东持股情况 | 序号 | 股东名称 | 持股数量（股） | 持股比例（%） | | --- | --- | --- | --- | | 1 | 上海之江药业有限公司 | 64,969,560 | 33.81 | | 2 | 上海之江生物科技股份有限公司 | 14,638,308 | 7.62 | | | 回购专用证券账户 | | | | 3 | 宁波康飞顿斯投资管理合伙企业 （有限合伙） | 6,002,000 | 3.12 | | 4 | 招商银行股份有限公司－广发价 值核心混合型证券投资基金 | 4,803,416 | 2.50 | | 5 | 宁波睿道创业投资合伙企业（有 | 2,995,199 | 1.56 | | | 限合伙） | | | | 6 | 中国银行股份有限公司－广发医 ...